Patents by Inventor Alastair Morgan Mackay

Alastair Morgan Mackay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150104431
    Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Application
    Filed: September 23, 2014
    Publication date: April 16, 2015
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
  • Patent number: 8852570
    Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: October 7, 2014
    Assignee: Mesoblast International Sarl
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
  • Patent number: 8852571
    Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: October 7, 2014
    Assignee: Mesoblast International Sarl
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
  • Patent number: 8852573
    Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: October 7, 2014
    Assignee: Mesoblast International Sarl
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
  • Patent number: 8852575
    Abstract: Disclosed are compositions and methods for method of treating a subject having reduced cardiac function or cardiac disease by administering adult bone marrow-derived stem cells to an individual. In some embodiments, the subject is a myocardial infarction patient or congestive heart failure patient. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: October 7, 2014
    Assignee: Mesoblast International Sarl
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
  • Patent number: 8852574
    Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: October 7, 2014
    Assignee: Mesoblast International Sarl
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
  • Patent number: 8852572
    Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: October 7, 2014
    Assignee: Mesoblast International Sarl
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
  • Publication number: 20120269784
    Abstract: Disclosed are compositions and methods for method of treating a subject having reduced cardiac function or cardiac disease by administering adult bone marrow-derived stem cells to an individual. In some embodiments, the subject is a myocardial infarction patient or congestive heart failure patient. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Application
    Filed: July 2, 2012
    Publication date: October 25, 2012
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
  • Publication number: 20120263682
    Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Application
    Filed: February 9, 2012
    Publication date: October 18, 2012
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
  • Publication number: 20120213749
    Abstract: Disclosed is a method for repairing or regenerating blood vessels in the heart of an individual, method of stimulating or promoting angiogenesis in the heart of an individual, or method of stimulating or promoting vascular endothelial growth factor (VEGF) expression in a heart of an individual by administering to the individual an effective amount of mesenchymal stem cells. These cells can be administered as a liquid injectable.
    Type: Application
    Filed: April 24, 2012
    Publication date: August 23, 2012
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
  • Publication number: 20120207716
    Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Application
    Filed: February 9, 2012
    Publication date: August 16, 2012
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
  • Publication number: 20120148545
    Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Application
    Filed: February 9, 2012
    Publication date: June 14, 2012
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
  • Publication number: 20120141437
    Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Application
    Filed: February 9, 2012
    Publication date: June 7, 2012
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
  • Publication number: 20120141438
    Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Application
    Filed: February 9, 2012
    Publication date: June 7, 2012
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
  • Patent number: 8158121
    Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: April 17, 2012
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
  • Patent number: 8158120
    Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: April 17, 2012
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
  • Publication number: 20110158964
    Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Application
    Filed: January 25, 2011
    Publication date: June 30, 2011
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
  • Publication number: 20110158965
    Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Application
    Filed: January 25, 2011
    Publication date: June 30, 2011
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
  • Patent number: 7892829
    Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: February 22, 2011
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
  • Publication number: 20100172884
    Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Application
    Filed: March 17, 2010
    Publication date: July 8, 2010
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay